ReviewBMC cancer2026
Pleomorphic adenoma: does the immunohistochemical profile direct the clinical profile: retrospective study and review of literature.
Review in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPleomorphic adenoma is a benign salivary gland tumor that has a potentiality to recurrence and malignant transformation as well. The genetic alteration of this tumor is not completely studied yet. Investigating the growth factor receptors and tumor microenvironment may yield answers to the nature of this tumor.
methodsThirty-six formalin-fixed, paraffin-embedded pleomorphic adenoma specimens were collected from Al-Mouassat University Hospital. EGFR, HER-2 and BCL-2 antibodies have been used in immunohistochemistry stains to investigate the most probable affected pathway in this progress of this tumor.
resultsImmunohistochemical analysis revealed total negativity for HER2 expression. While, EGFR and BCL-2 expression was positive in diffuse patchy pattern. The positivity was membranous and/or cytoplasmic predominantly within the tumor cell population. Statistical analysis revealed no significant association between EGFR/BCL-2 expression and patient gender (p = 0.848) or tumor site (p = 1.000). The absence of HER2 expression was consistent across all cases, regardless of clinicopathological parameters. The expression of EGFR and BCL2 did not show a statistically significant correlation with demographic variables, suggesting a tumor-intrinsic expression pattern rather than dependence on clinical factors.
conclusionOn this study, pleomorphic adenoma demonstrated a distinct immune-profile with positivity of EGFR and BCL-2 and negative expression of HER-2. These findings suggest HER-2 unlikely contribute to tumor behavior, meanwhile the positivity of EGFR and BCL-2 may be related to the tumor survival rather than malignant transformation. Moreover, these markers do not same to consider as reliable predictors of malignant transformation in pleomorphic adenoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.